TriSalus Life Sciences, Inc.
TLSI Nasdaq
SEC CIK 1826667
Follow TriSalus Life Sciences
Weekly email: filings, results
Revenue, last quarter
$12.9M
+11.3% vs same quarter last year
Net income
−$8.9M
+18.1% vs same quarter last year
EPS, diluted
−$0.15
+84.4% vs same quarter last year
Operating cash flow
−$5.3M
−42.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $45.2M | −$39.2M |
| FY24 | $29.4M | −$30M |
| FY23 | $18.5M | −$59.4M |
| FY22 | $12.4M | −$47.2M |
| FY21 | - | $4.8M |
| FY20 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 84.6% | −59.7% | −86.9% |
| FY24 | 86.1% | −122.9% | −102.1% |
| FY23 | 85.9% | −294.3% | −320.7% |
| FY22 | 81.8% | −293.9% | −380.6% |
| FY21 | - | - | - |
| FY20 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$18.9M |
| FY24 | −$41.2M |
| FY23 | −$51.2M |
| FY22 | −$33M |
| FY21 | - |
| FY20 | - |
- TriSalus Life Sciences
- Healthcare median
Show the numbers
| Year | TriSalus Life Sciences | Healthcare median |
|---|---|---|
| FY25 | −86.9% | −30.6% |
| FY24 | −102.1% | −47% |
| FY23 | −320.7% | −58% |
| FY22 | −380.6% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |